secwatch.observer — SEC 8-K summary
======================================

Issuer:     Veradermics, Inc (MANE)
CIK:        0001827635
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001827635-26-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veradermics reports FY 2025 net loss $70M; cash $141.9M; IPO raised $295M; two pivotal trials enrolled
--------------------------------------------------------------------------------

- FY 2025 net loss $70.0M vs $26.5M in 2024; Q4 net loss $21.8M vs $5.7M.
- Cash, equivalents & marketable securities $141.9M at Dec 31, 2025; upsized IPO added $294.8M gross in Feb 2026.
- R&D expenses FY 2025 $62.1M (up $38.8M YoY) driven by VDPHL01 clinical development and headcount.
- Enrollment completed in Phase 2/3 Study 302 (male PHL) and confirmatory Study 304; topline data 1H and 2H 2026.
- Appointed Mark Neumann as Chief Commercial & Strategy Officer; Study 306 enrolling for female PHL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/0001827635-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/mane-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001827635-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer